
Advent Life Sciences
London life-sciences venture firm; co-led T-Therapeutics' $133m Series B with the British Business Bank.
Last refreshed: 14 November 2026 · Appears in 1 active topic
Why does the British Business Bank keep backing biotech beside Advent?
Timeline for Advent Life Sciences
Co-led T-Therapeutics' Series B
UK Startups and Innovation: T-Therapeutics raises $133m in Series BBackground
Advent Life Sciences, a London venture firm that invests in drug and medical-technology companies, co-led T-Therapeutics' $133m Series B on 5 November 2026 with the British Business Bank. The Bank called it its third co-investment beside Advent.
Advent spun out of Advent Venture Partners and has offices in London, Paris and Boston. Its general partner Dominic Schmidt said T-cell engagers had succeeded in blood cancers but had been held back in solid tumours, the gap T-Therapeutics targets. It is a separate firm from the buyout group Advent International.
Who is Advent Life Sciences?
Is Advent Life Sciences part of Advent International?
How often has the British Business Bank invested with Advent Life Sciences?
Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 14 November 2026. Editorial standards.